3-乙烯基吡啶-2(1H)-酮 | 395681-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-乙烯基吡啶-2(1H)-酮
• 英文名称: 3-vinylpyridin-2(1H)-one
• 英文别名: Vinyl Pyridone；3-ethenyl-1H-pyridin-2-one
• CAS: 395681-47-7
• 化学式: C₇H₇NO
• mdl: MFCD18427747
• 分子量: 121.139
• InChiKey: KNHYFBCCUHCLGL-UHFFFAOYSA-N

物化性质

• 熔点：
  38-39 °C
• 沸点：
  339.4±15.0 °C(Predicted)
• 密度：
  1.160±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  乙烯三氟硼酸钾 、 3-溴-2-羟基吡啶 在 2% Pd/C 、 potassium acetate 作用下， 以 N-甲基吡咯烷酮 、 水 为溶剂， 反应 0.33h， 以81%的产率得到3-乙烯基吡啶-2(1H)-酮
  参考文献：
  名称：

  微波辅助钯催化 2(1H)-吡啶酮的多相乙烯基化

  摘要：

  使用乙烯基三氟硼酸钾和碳载钯作为催化剂，开发了一种温和有效的 2(1H)-吡啶酮的微波辅助乙烯基化。已经筛选了各种乙烯基化试剂、Pd 源和溶剂。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)

  DOI：

  10.1002/ejoc.200900677

文献信息

• [EN] PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS<br/>[FR] ANALOGUES DE PYRIDONE UTILES COMME ANTAGONISTES DU RÉCEPTEUR 1 DE L'HORMONE CONCENTRANT LA MÉLANINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010104830A1

  公开（公告）日：2010-09-16

  MCHR1 antagonists are provided having the following Formula I: wherein A1 and A2 are independently C or N; E is C or N; D1 is a bond, -CR8R9X-, -XCR8R9-, -CHR8CHR9-, -CR10=CR10'-, -C≡C-, or 1,2-cyclopropyl; X is O, S or -NR11; R1, R2, and R3 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, lower cycloalkoxy, -CF3, -OCF3, -OR12 and -SR12; G is O or S; D2 is lower alkyl, lower cycloalkyl, lower alkylcycloalkyl, lower cycloalkylalkyl, lower cycloalkoxyalkyl or lower alkycycloalkoxy; Z1 and Z2 are independently hydrogen, halogen, lower alkyl, lower cycloalkyl, lower alkoxy, lower cycloalkoxy, halo, -CF3, -OCONR14R14', -CN, -CONR14R14', -SOR12, -SO2R12, -NR14COR14', -NR14CO2R14', -CO2R12, NR14SO2R12 or -COR12 provided that if Z1 is -CH3 and one of R1, R2, or R3 is F, then Z2 cannot be H;; R5, R6, and R7 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, -CF3, -SR12, lower alkoxy, lower cycloalkoxy, -OCH2OMe, -CN, -CONR14R14', SOR12, SO2R12, NR14COR14', NR14CO2R12, CO2R12, NR14SO2R12 and -COR12; R8, R9, R10, R10', R11 are independently hydrogen or lower alkyl; R12 is lower alkyl or lower cycloalkyl; and R14 and R14' are independently H, lower alkyl, lower cycloalkyl or R14 and R14' together with the N to which they are attached form a ring having 4 to 7 atoms. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.

  MCHR1拮抗剂具有以下的化学式I：其中A1和A2独立地为C或N；E为C或N；D1为键，-CR8R9X-，-XCR8R9-，-CHR8CHR9-，-CR10=CR10'-，-C≡C-，或1,2-环丙基；X为O，S或-NR11；R1、R2和R3独立地选自氢、卤素、低烷基、低环烷基、低环氧基、-CF3、-OCF3、-OR12和-SR12的组；G为O或S；D2为低烷基、低环烷基、低烷基环烷基、低环烷基烷基、低环氧基烷基或低烷基环氧基；Z1和Z2独立地为氢、卤素、低烷基、低环烷基、低烷氧基、低环氧基、卤、-CF3、-OCONR14R14'、-CN、-CONR14R14'、-SOR12、-SO2R12、-NR14COR14'、-NR14CO2R14'、-CO2R12、NR14SO2R12或-COR12，但如果Z1为-CH3且R1、R2或R3中有一个为F，则Z2不能为H；R5、R6和R7独立地选自氢、卤素、低烷基、低环烷基、-CF3、-SR12、低烷氧基、低环氧基、-OCH2OMe、-CN、-CONR14R14'、SOR12、SO2R12、NR14COR14'、NR14CO2R12、CO2R12、NR14SO2R12和-COR12；R8、R9、R10、R10'、R11独立地为氢或低烷基；R12为低烷基或低环烷基；R14和R14'独立地为H、低烷基、低环烷基或R14和R14'与它们连接的N一起形成具有4至7个原子的环。这类化合物对于治疗MCHR1介导的疾病，如肥胖症、糖尿病、炎症性肠病、抑郁症和焦虑症是有用的。
• [EN] 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS<br/>[FR] DÉRIVÉS D'INDOLE SUBSTITUÉS EN 2 ET 3 POUR TRAITER DES INFECTIONS VIRALES
  申请人：SCHERING CORP

  公开号：WO2009032116A1

  公开（公告）日：2009-03-12

  The present invention relates to 2,3-Substituted Indole Derivatives, compositions comprising at least one 2,3-Substituted Indole Derivative, and methods of using the 2,3-Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

  本发明涉及2,3-取代吲哚衍生物，包含至少一种2,3-取代吲哚衍生物的组合物，以及使用这些2,3-取代吲哚衍生物治疗或预防患者病毒感染或病毒相关疾病的方法。
• [EN] ANTIDIABETIC BICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014130608A1

  公开（公告）日：2014-08-28

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新型化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，可能在治疗、预防和抑制由G蛋白偶联受体40介导的疾病方面具有用处。本发明的化合物可能在治疗2型糖尿病以及与该疾病常相关的病症方面有用，包括肥胖和脂质紊乱，如混合性或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症。
• Molecularly imprinted phosphate binders for therapeutic use
  申请人：Ross Allan Edward

  公开号：US20050276781A1

  公开（公告）日：2005-12-15

  Methods for synthesizing molecularly imprinted polymers (MIP) having an affinity for dietary phosphates, resulting polymers, pharmaceutical compositions and modes of administration are disclosed. The MIP compounds are useful for binding excess dietary phosphates in a patient in need thereof.

  本发明揭示了一种合成分子印迹聚合物（MIP）的方法，其具有亲和力，可用于膳食磷的合成，所得的聚合物，制药组合物和给药方式。MIP化合物可用于在需要的患者中结合过量的膳食磷。
• Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia
  申请人：Tomiyama Hiroshi

  公开号：US20080119441A1

  公开（公告）日：2008-05-22

  This invention related to a series of new phosphonic acid derivatives having anti-hyperphosphatemia activity. (I) [wherein: A is selected from —(CH 2 ) n —, —CO—, —(CH 2 ) n —CO—(CH 2 ) m —, —(CH 2 ) n —CS—(CH 2 ) m — or branched alkylene group. B ring and C ring are selected from benzene ring, naphthalene ring, azulene ring or, heterocycle or fused heterocycle. D is —(CH 2 ) (n+1) —, —(CH2)-O—(CH 2 ) m —, —(CH 2 )—S(O) o —(CH 2 ) m —, —CF 3 or —(CH 2 ) n —NR 10 —(CH 2 ) m — (wherein: D ring is connected with the carbon atom composing C ring.) E is selected from oxygen atom or sulfur atom. P is phosphine atom. R 1 ˜R 7 (wherein R 1 and R 2 , R 4 and R 5 are joined together with neighbored carbon atom to form 5˜7 membered saturated or unsaturated hydrocarbon ring, or 5˜6 membered fused heterocycle. R 1 , R 2 and R 3 are not hydrogen atom if B ring is benzene ring.) may be the same or different and are substituents. R 8 and R 9 are may be the same or different and are substituents. R 10 is alkyl group. n and m are 0-10. o is 0-2.

  本发明涉及一系列具有抗高磷血症活性的新磷酸衍生物(I) [其中：A选自—(CH2)n—、—CO—、—(CH2)n—CO—(CH2)m—、—(CH2)n—CS—(CH2)m—或支链烷基。B环和C环选自苯环、萘环、蓝环或杂环或融合杂环。D选自—(CH2)(n+1)—、—(CH2)-O—(CH2)m—、—(CH2)—S(O)o—(CH2)m—、—CF3或—(CH2)n—NR10—(CH2)m—（其中：D环与组成C环的碳原子相连）。E选自氧原子或硫原子。P为磷原子。R1˜R7（其中R1和R2，R4和R5与相邻的碳原子结合形成5˜7个成员的饱和或不饱和碳氢化合物环，或5˜6个成员的融合杂环。如果B环为苯环，则R1、R2和R3不是氢原子。）可能相同或不同，并且是取代基。R8和R9可能相同或不同，并且是取代基。R10是烷基。n和m为0-10。o为0-2。